UNSPSC 51141521: Mesuximide or methsuximide

This classification denotes an anticonvulsant agent with the molecular formula C12H13NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 0G76K8X6C0, chemically known as 2,5-pyrrolidinedione,1,3-dimethyl-3-phenyl- but more generally known as mesuximide, which bears US NIH Compound Identifier 6476. European Medicines Agency schedules Mesuximide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08797MIG.

UNSPSC 51141521 Mesuximide or methsuximide is a Commodity code that covers specific anticonvulsant pharmaceutical products. State and local procurement activity under this code, however, shows a marked mismatch: recent solicitations tagged to this code involve naloxone (an opioid antagonist), direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals—none of which are mesuximide or methsuximide derivatives. The actual buying activity under this code designation reflects broader pharmaceutical procurement including emergency medical supplies, pharmacy benefit management programs, and generic drug sourcing rather than the narrow therapeutic class the code nominally describes. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon).

Recent opportunities span Florida, Texas, and Minnesota-Oregon. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2026. Texas HHS released RFI No. HHS0017013 on April 3, 2026, requesting vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Department of Administration, administering MMCAP, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and over-the-counter products through authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.), with proposals due March 26, 2026, and contract effectiveness July 1, 2026. All three solicitations require vendor compliance with Drug Supply Chain Security Act standards, cGMP certification, or E-Verify requirements, and involve fixed or competitive pricing models with multi-year terms and optional renewals.